BPC-157 for Dogs
Body Protection Compound-157
The short answer
BPC-157 has the most directly relevant safety data of any compound on this site as it applies to dogs. A dedicated preclinical toxicity evaluation covering mice, rats, rabbits and dogs reported that it was well tolerated with no serious toxicity, no genotoxicity and no embryo-fetal toxicity; the single notable finding was a decrease in creatinine at 2 mg/kg, which resolved spontaneously after two weeks of withdrawal and did not occur at lower doses. Local irritation was mild. The meaningful caveat is duration rather than dose — those studies covered single and repeated dosing, not months of continuous administration.
What it is and how it is thought to work
BPC-157 is a short chain of fifteen amino acids originally identified in gastric juice. Research describes it encouraging the growth of new blood vessels into damaged tissue, which is the rate-limiting step in most healing. Studies also report a protective effect on the lining of the gut. It is the one compound here with a published pharmacokinetic study performed in dogs, which is why it appears first on almost every canine protocol.
Mechanism in clinical terms
Investigated for angiogenesis via VEGFR2 upregulation and modulation of the nitric oxide / eNOS system, alongside acceleration of tendon-to-bone healing in rodent models. Pharmacokinetics in beagle dogs show mean absolute bioavailability of 45-51% by intramuscular injection, an elimination half-life under 30 minutes, and linear kinetics across the doses tested. Principal excretory pathways are urinary and biliary. A separate preclinical evaluation across mice, rats, rabbits and dogs reported good tolerance on repeated dosing, the only notable finding being a reversible decrease in creatinine at 2 mg/kg that resolved after two weeks of withdrawal.
Canine dosing by weight class
Figures below are reported as they appear in the source literature. They are not recommendations, and dosing for an individual dog must be set by a veterinarian.
Small / toy breed
under 22 lb (10 kg)
- Reported dose
- 4–100 mcg per day
- Frequency
- Once daily
- Duration
- 2-4 weeks
- Studied for
- Gastrointestinal issues, joint injury, post-surgical recovery
Medium breed
22–77 lb (10–35 kg)
- Reported dose
- 20–350 mcg per day
- Frequency
- Once daily
- Duration
- 2-8 weeks
- Studied for
- Tendon and ligament injury, gut protection, wound healing
Large / giant breed
over 77 lb (35 kg)
- Reported dose
- 70–600 mcg per day
- Frequency
- Once daily
- Duration
- 2-8 weeks
- Studied for
- Orthopaedic recovery, chronic degenerative conditions
Route matters
The weight-based figures above are for INJECTABLE (subcutaneous) use. Oral BPC-157 is dosed differently: because oral bioavailability is much lower, it is given as a flat ~0.25-0.5 mg per day regardless of body weight (commonly a single 0.5 mg dose daily, up to 0.5 mg twice daily for large dogs or gut-focused use). Do not apply the injectable per-kg calculation to oral capsules.
Need a figure for a specific weight? Use the dose calculator, or see the weight-specific pages: small / toy breed, medium breed, large / giant breed.
Contraindications and warnings
Read these before anything else on the page.
Limited long-term canine data
The published canine work covers short-duration dosing. Multi-month continuous administration in dogs has not been formally studied, so extended use should be a deliberate decision made with your veterinarian rather than a default.
Angiogenic mechanism has not been evaluated in cancer
No cancer contraindication is established for BPC-157, and its preclinical safety work reported no tumour-promoting signal. It is still worth being explicit about why the question comes up: the angiogenesis this compound is investigated for is the same process that makes TB-500 contraindicated in malignancy. The difference is that BPC-157 has not been formally evaluated in that setting, not that it has been cleared. In a dog with known or suspected cancer this is a question for a veterinary oncologist rather than an assumption in either direction.
Example research protocol
A representative timeline drawn from the published literature, showing what is monitored and when. Any actual protocol should be set by the veterinarian managing the case.
- 1Day 1Baseline and first dose
What owners observe
Mild lethargy in the first 24 hours is commonly reported and self-limiting. Appetite and water intake should be unchanged. Photograph the injury and note how your dog is bearing weight so you have something to compare against.
Clinical monitoring
Baseline CBC and chemistry panel. Document injection sites for rotation. Elimination half-life is under 30 minutes following intramuscular administration, with bioavailability reported at 45-51% in beagle dogs.
- 2Week 2Early response assessment
What owners observe
Greater willingness to put weight on the affected limb is the earliest reliable signal. Many owners report more energy on walks and a better appetite before any visible change in the injury itself.
Clinical monitoring
Palpate the injury site for reduced swelling and heat. Re-score gait. Confirm injection sites are rotating and no nodules have formed.
- 3Week 4Transition decision
What owners observe
Substantial mobility gains are typical by this point — stairs, play, and normal-length walks. This is the checkpoint where you and your vet decide whether to continue, taper, or stop.
Clinical monitoring
Inflammatory markers trending down. Repeat imaging where applicable may show tissue consolidation. If running a combined protocol, this is where TB-500 moves to its maintenance dose.
- 4Week 8Protocol completion
What owners observe
Full return to normal activity with the improvement holding steady rather than fluctuating. Sustained quality of life is the endpoint that matters, not any single measurement.
Clinical monitoring
Follow-up imaging to confirm repair. Gait analysis normalised. For chronic conditions a reduced maintenance schedule of three times weekly is sometimes continued under veterinary direction.
What BPC-157 is investigated for
Wound healing
Repair of surgical incisions, lacerations, ulcers, and chronic non-healing wounds.
Post-surgical recovery
Supporting tissue repair, comfort, and return to function after an orthopaedic or soft tissue procedure.
IBD and gut health
Chronic inflammation of the intestinal lining causing vomiting, diarrhoea, and weight loss.
Tendon and ligament injury
Strains, partial tears, and chronic tendinopathies in working, sporting, and active dogs.
Cranial cruciate ligament (CCL) tear
Rupture of the stabilising ligament in the stifle, the single most common orthopaedic injury in dogs.
Osteoarthritis
Progressive cartilage loss and joint inflammation, affecting a large share of dogs over eight years old.
How it compares
- BPC-157 vs TB-500 for dogs — how BPC-157 differs from TB-500
- BPC-157 vs GHK-Cu for dogs — how BPC-157 differs from GHK-Cu
- BPC-157 vs IGF-1 LR3 for dogs — how BPC-157 differs from IGF-1 LR3
- BPC-157 vs Fenbendazole for dogs — how BPC-157 differs from Fenbendazole
Common questions
Is BPC-157 safe for dogs?+
BPC-157 has the most directly relevant safety data of any compound on this site as it applies to dogs. A dedicated preclinical toxicity evaluation covering mice, rats, rabbits and dogs reported that it was well tolerated with no serious toxicity, no genotoxicity and no embryo-fetal toxicity; the single notable finding was a decrease in creatinine at 2 mg/kg, which resolved spontaneously after two weeks of withdrawal and did not occur at lower doses. Local irritation was mild. The meaningful caveat is duration rather than dose — those studies covered single and repeated dosing, not months of continuous administration.
How much BPC-157 should I give my dog?+
Reported doses vary by weight class. Small / toy breed (under 22 lb (10 kg)): 4–100 mcg per day, once daily. Medium breed (22–77 lb (10–35 kg)): 20–350 mcg per day, once daily. Large / giant breed (over 77 lb (35 kg)): 70–600 mcg per day, once daily. These figures are reported as they appear in the source literature and are not recommendations — dosing for an individual dog must be set by a veterinarian who has examined the animal.
How is BPC-157 given to dogs?+
BPC-157 is administered by subcutaneous injection or intramuscular injection or oral administration. See the injection guide and reconstitution guide for handling detail.
What is the evidence for BPC-157 in dogs?+
BPC-157 is graded as emerging evidence on this site, drawing on 6 cited studies. BPC-157 is a short chain of fifteen amino acids originally identified in gastric juice. Research describes it encouraging the growth of new blood vessels into damaged tissue, which is the rate-limiting step in most healing. Studies also report a protective effect on the lining of the gut. It is the one compound here with a published pharmacokinetic study performed in dogs, which is why it appears first on almost every canine protocol.
References
- 1.CANINE STUDYHe L, Feng D, Guo H, et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Frontiers in Pharmacology, 2022. PMID 36588717
- 2.CANINE STUDYXu C, Sun L, Ren F, et al. Preclinical safety evaluation of body protective compound-157, a potential drug for treating various wounds. Regulatory Toxicology and Pharmacology, 2020. PMID 32334036
- 3.Vasireddi N, Nguyen HH, Ahmed WA, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS Journal, 2025. PMID 40756949
- 4.Gwyer D, Wragg NM, Wilson SL Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell and Tissue Research, 2019. PMID 30915550
- 5.Józwiak M, Bauer M, Kamysz W, Kleczkowska P Multifunctionality and Possible Medical Application of the BPC 157 Peptide — Literature and Patent Review. Pharmaceuticals, 2025. PMID 40005999
- 6.Mayfield CK, et al. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. American Journal of Sports Medicine, 2026. PMID 41476424
Educational information — not veterinary medical advice
Everything on this page is compiled from published peer-reviewed literature for educational and research purposes. It does not establish a veterinarian-client-patient relationship (VCPR) and is not a substitute for veterinary examination and diagnosis. Most compounds described here are investigational or used off-label and are not FDA-approved for these purposes in dogs. Extralabel drug use in animals requires a valid VCPR and the direct supervision of a licensed veterinarian under AMDUCA (21 U.S.C. §360b). Dosing figures are reported as they appear in the source literature and are not recommendations.